221 related articles for article (PubMed ID: 10557559)
1. CBER status on reform initiatives: industry reactions and comments.
Page M
Food Drug Law J; 1997; 52(2):193-6. PubMed ID: 10557559
[No Abstract] [Full Text] [Related]
2. International Conference on Harmonisation; guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin; availability--FDA. Notice.
Fed Regist; 1998 Sep; 63(185):51074-84. PubMed ID: 10185809
[TBL] [Abstract][Full Text] [Related]
3. Combination products regulation at the FDA.
Lauritsen KJ; Nguyen T
Clin Pharmacol Ther; 2009 May; 85(5):468-70. PubMed ID: 19381151
[TBL] [Abstract][Full Text] [Related]
4. The impact of FDA reform.
Trunzo J
Med Device Technol; 2003 Apr; 14(3):36-7. PubMed ID: 12789699
[TBL] [Abstract][Full Text] [Related]
5. Current regulatory and legal considerations for follow-on biologics.
Kingham RF; Lietzan E
Clin Pharmacol Ther; 2008 Nov; 84(5):633-5. PubMed ID: 18716615
[No Abstract] [Full Text] [Related]
6. International Conference on Harmonisation; guidance on quality of biotechnological/biological products: derivation and characterization of cell substrates used for production of biotechnological/biological products; availability. Notice. Food and Drug Administration, HHS.
Fed Regist; 1998 Sep; 63(182):50244-9. PubMed ID: 12269373
[TBL] [Abstract][Full Text] [Related]
7. SuperGenerics: a better alternative for biogenerics.
Charles SA
Drug Discov Today; 2005 Apr; 10(8):533-5. PubMed ID: 15837591
[No Abstract] [Full Text] [Related]
8. The FDA and "privatization"--the drug approval process.
Rutherford EM
Food Drug Law J; 1995; 50 Spec():203-25. PubMed ID: 10343044
[No Abstract] [Full Text] [Related]
9. Well-characterized biotechnology products: evolving to meet the needs of the 21st century.
Zoon KC
Dev Biol Stand; 1998; 96():3-8. PubMed ID: 9890510
[No Abstract] [Full Text] [Related]
10. FDA transparency rules could hit small companies hardest.
Allison M
Nat Biotechnol; 2010 Aug; 28(8):767-8. PubMed ID: 20697386
[No Abstract] [Full Text] [Related]
11. Who would approve new drugs if there were no FDA?
Gatty B
Hosp Formul; 1995 Jan; 30(1):58, 57. PubMed ID: 10139726
[No Abstract] [Full Text] [Related]
12. The federal preemption debate in pharmaceutical labeling product liability actions.
Gross JM; Curry JA
Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
[No Abstract] [Full Text] [Related]
13. Takings issues in the approval of generic biologics.
Yoo JC
Food Drug Law J; 2005; 60(1):33-43. PubMed ID: 15940853
[No Abstract] [Full Text] [Related]
14. Biosimilars legislation awakens data exclusivity debate.
Hutson S
Nat Med; 2009 Nov; 15(11):1242. PubMed ID: 19893548
[No Abstract] [Full Text] [Related]
15. Institutional review boards and approval of new products without human subjects research.
Maloney DM
Hum Res Rep; 2002 Jul; 17(7):1-2. PubMed ID: 12731489
[No Abstract] [Full Text] [Related]
16. Characterization of gene therapy products and the impact of manufacturing changes on product comparability.
Simek SL
Dev Biol (Basel); 2005; 122():139-44. PubMed ID: 16375258
[TBL] [Abstract][Full Text] [Related]
17. International Conference on Harmonisation; guidance on specifications: test procedures and acceptance criteria for biotechnological/biological products. Notice. Food and Drug Administration, HHS.
Fed Regist; 1999 Aug; 64(159):44928-35. PubMed ID: 12356094
[TBL] [Abstract][Full Text] [Related]
18. Off-label or off-limits?
Ratner M; Gura T
Nat Biotechnol; 2008 Aug; 26(8):867-75. PubMed ID: 18688236
[No Abstract] [Full Text] [Related]
19. Bills target biosimilar drugs.
Wadman M
Nature; 2009 Mar; 458(7237):394-5. PubMed ID: 19325595
[No Abstract] [Full Text] [Related]
20. Reform bill to speed drugs to residents.
Hawryluk M
Provider; 1997 Nov; 23(11):37-8. PubMed ID: 10173669
[No Abstract] [Full Text] [Related]
[Next] [New Search]
